NCT04671251: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

NCT04671251: Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

This is a multicenter, open-label, dose-escalation Phase 1b study of AEVI-007 in subjects with relapsed or refractory Multiple Myeloma.

The objectives of the study are to evaluate the safety, pharmacokinetics and pharmacodynamics of AEVI-007.

Sponsor

Avalo Therapeutics, Inc.

Multiple Locations

---

ClinicalTrials.gov Identifier: NCT04671251

Official Title: A Multicenter, Open-Label, Dose-Escalation Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

First Posted : December 17, 2020

Click here to see details on ClinicalTrials.gov

---

Drug: AEVI-007

Anti-IL-18 Monoclonal Antibody CERC-007 (Code C179215)

AEVI-007

Anti-IL-18 Monoclonal Antibody CERC-007

CERC 007

CERC-007

CERC007

MEDI2338

CERC-007 (formerly AEVI-007)

---

Locations

United States, California

United States, Florida

United States, Maryland

United States, North Carolina

United States, Wisconsin